Authors analyzed PrEP prescription data from a subsample of adult women participating in the TIARAS (Efficacy of a Trauma Intervention for Affect Regulation, Adherence, and Substance Use to Optimize PrEP for Women Who Inject Drugs) randomized trial.  Participants (n=62) were enrolled at a large community-based syringe services program in the mid-Atlantic U.S.: 69% were homeless and 97% engaged in polysubstance use (82% reported injecting approximately 6 times per day).  33% and 48% reported sharing syringes and sex exchange, respectively.  Over a third (n=19) had prior PrEP experience: 6 had previously taken oral PrEP, 7 had received long-acting injectable cabotegravir, and 6 had experience with both.  Each received individualized counseling with program navigators, selected their preferred PrEP formulation, then underwent laboratory screening.  People who selected long-acting injectable cabotegravir returned for a one-week follow-up which included clinical evaluation and the first injection.  Most (89%) participants opted for long-acting injectable PrEP—no specific demographic factors were significantly associated with PrEP modality selection.  However, some HIV risk behaviors were associated: women who selected injectable PrEP reported an average of 2 sex partners within 6 months (compared to none among women selecting oral PrEP), and women who reported daily injection drug use also preferred injectable PrEP.